Discussion of unique properties of botulinum toxins.

, A., Discussion of unique Acomment aboutAndyPickett’s slides,which attempted to show similarity to the Diane Tang-Liu and Roger Aoki paper (Tang-Liu et al., 2003). In the first two papers, those were saturateddoses, and theywereperformed fordifferent purposes and cannot really be used in the way Andy Pickett used them. The other issue is on the definitions. I think now we are all very confused, and even now Alan Scott and it sounds like Joe Arezzo, by Andy Pickett’s definition, are misguided; so I’m a little concerned about that. One of the questions I have for Andy Pickett is: in the clinical world there is a wealth of data that compare different toxins in terms of dysphagia rate, and if you look across all the toxins I think it is very clear that Dysport, Botox, and Myobloc have different profiles. Temporarily putting the animal studies aside, how do you explain that?